Inspection Record

OPS International Inc dba Olympia Pharmaceuticals — FDA 483 Findings

US FDAInspected 2026-09-03Published 2026-10-01 8 findingsProcess validationMaterial and supplier controlAseptic processing and sterility assuranceLaboratory and QC controls

Inspectors Mindy M Chou · Michelle LinThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

2Material and supplier control

Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

3Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

4Aseptic processing and sterility assurance

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

5Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

6Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

7Laboratory and QC controls

The written stability program for drug products does not include reliable, meaningful and specific test methods.

8Material and supplier control

Each component is not added to the batch by one person and verified by a second person ..

About this record

Extracted automatically from the document US FDA published on 2026-10-01. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

OPS International Inc dba Olympia Pharmaceuticals company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.